Evolutions in Hepatocellular Carcinoma in the Era of COVID-19 - Episode 1

Evolutions in Hepatocellular Carcinoma in the Era of COVID-19

This OncLive webinar will focus on best practices and multidisciplinary approaches in the management of hepatocellular carcinoma and the impact of the COVID-19 pandemic on patients with HCC.

  • How the pandemic has impacted the diagnosis of patients with HCC
  • Current approaches to surgery, transplant and radiotherapy for patients with HCC
  • Considerations for treatment strategies in HCC in the era of COVID-19

Kevin Kim, MD


Kevin Kim, MD

Professor of Radiology and Biomedical Imaging

Professor of Medicine (Medical Oncology)

Section Chief, Interventional Radiology

Reena J. Salgia, MD

Reena J. Salgia, MD

Medical Director, Liver Cancer Clinic

Program Director, Gastroenterology/Transplant Hepatology Fellowship

Senior Staff Physician, Hepatology

Henry Ford Hospital

Michael Morse, MD, MHS, FACP

Michael Morse, MD, MHS, FACP

Professor of Medicine

Professor in the Department of Surgery

Gastrointestinal Oncology

Duke University Health System

Richard S. Finn, MD

Richard S. Finn, MD

Professor of Clinical Medicine

Department of Medicine, Division of Hematology/Oncology

Geffen School of Medicine, University of California, Los Angeles (UCLA)

Director of the Signal Transduction and Therapeutics Program

Jonsson Comprehensive Cancer Center at UCLA

Sponsored by: Genentech